Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients

@article{Neggers2010ConversionOD,
  title={Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients},
  author={Sebastian Neggers and Wouter W. de Herder and Richard A. Feelders and Aart J van der Lely},
  journal={Pituitary},
  year={2010},
  volume={14},
  pages={253 - 258}
}
The efficacy of combined treatment in active acromegaly with both long-acting somatostatin analogs (SRIF) and pegvisomant (PEG-V) has been well established. The aim was to describe the PEG-V dose reductions after the conversion from daily PEG-V to combination treatment. To clarify the individual beneficial and adverse effects, in two acromegaly patients, who only normalized their insulin like growth factor (IGF-I) levels with high-dose pegvisomant therapy. We present two cases of a 31 and 44… Expand
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
TLDR
An overview of the efficacy and safety of the combined treatment of LA-SSAs with PEGV is provided, finding that tumor size control or even tumor shrinkage can be observed in a vast majority of patients. Expand
Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
TLDR
The combination treatment with LA-SRIFs and P EGV was effective in 97% of the patients, it appears to be a safe medical treatment and it reduces the required dose of PEGV. Expand
Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
  • S. Neggers, A. J. van der Lely
  • Medicine
  • Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2011
TLDR
Combination treatment with somatostatin analogues and pegvisomant (a growth-hormone-receptor antagonist) seems to be an attractive option at normalising the level of insulin-like growth factor 1 in over 90% of patients and has a favourable effect on quality of life in those with biochemically controlled acromegaly. Expand
Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections
TLDR
Excessive growth hormone secretion persisting after pituitary surgery and irradiation can be controlled in a convenient way for the patient with acromegaly by combining monthly lanreotide and weekly pegvisomant injections, if monotherapy with a somatostatin analog fails. Expand
Investigational therapies for acromegaly
TLDR
Novel SSA formulations and new molecules under investigation in clinical trials, such as the SSA multi-receptor ligand, pasireotide, which represents a promising option therapy, especially in patients not adequately controlled with currently available SSA, are suggested. Expand
Pegvisomant Treatment in Acromegaly
TLDR
Clinical studies and cohorts that have documented the efficacy of pegvisomant monotherapy and combined therapy are reviewed and a concise overview of associated side effects are given. Expand
The role of combination medical therapy in the treatment of acromegaly
TLDR
While the combination of SRL and cabergoline was generally well tolerated, a lower baseline insulin-like growth factor-1 (IGF-1) level was the best predictor of efficacy; this combination may be most effective in patients with mildly elevated IGF-1. Expand
Octreotide-Resistant Acromegaly: Challenges and Solutions
TLDR
The current literature about the management of acromegaly is revised, aiming to highlight the most relevant and recent therapeutic strategies proposed for patients resistant to first-line medical therapy. Expand
Update on the use of oral octreotide therapy for acromegaly
TLDR
Oral octreotide is a novel and effective treatment for acromegaly and the side effects have been shown to be comparable to the injectable SSAs, but the long-term effect is still elusive. Expand
Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening
TLDR
Treatment of pituitary gigantism is frequently challenging; delayed control increases the harmful effects of GH excess, such as, excessive stature and symptom burden, so early diagnosis and effective treatment are particularly important in these cases. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 27 REFERENCES
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
TLDR
Dose of pegvisomant was increased until IGF-I concentration became normal or until a weekly dose of 80 mg was reached, and the combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients. Expand
Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
TLDR
Long-term combined treatment with long-acting SSA and (twice) weekly PEG-V for active acromegaly seems to be effective and safe and patients with acromegalic patients seem to have a higher risk of developing transient liver enzyme disturbances. Expand
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
TLDR
Long-term combined treatment with SSA and twice weekly PEG-V up to more than 4 years seems to be safe and a clinical significant decrease in tumor size was observed in 14 patients during combined treatment. Expand
Somatostatin analog and pegvisomant combination therapy for acromegaly
TLDR
Combination treatment with somatostatin analogs and pegvisomant is highly effective at normalizing the level of insulin-like growth factor I in over 90% of patients and might also have a favorable effect on quality of life in those with biochemically controlled acromegaly. Expand
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
TLDR
Improvement in quality of life was observed after the addition of 40 mg pegvisomant weekly to monthly SSA therapy in acromegalic patients who had normalized IGF-I on SSA monotherapy, and the findings question the validity of the current approach of medical treatment. Expand
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
TLDR
Pegvisomant is an effective medical treatment for acromegaly and of the patients treated for 12 months or more, 87 of 90 (97%) achieved a normal serum IGF-1 concentration. Expand
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
TLDR
Dual blockade of the GH axis with pegvisomant and a SMS analog is feasible in acromegaly. Expand
Long-term effects of pegvisomant in patients with acromegaly
TLDR
The long-term data that have been gathered on pegvisomant therapy are presented, the related risks and benefits are discussed, and a potential therapeutic approach is frame. Expand
A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long‐acting octreotide in patients with acromegaly
Objective  For patients with acromegaly who are suboptimally controlled on long‐acting octreotide (LAR), treatment options are to switch to pegvisomant monotherapy (PM) or add pegvisomant to LARExpand
A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal.
TLDR
Pegvisomant, unlike octreotide, is not associated with deterioration in glucose tolerance and impairment of stimulated gut hormone release in normal males, according to an open-label, random-order, cross-over study. Expand
...
1
2
3
...